PROTAC ERα Degrader-1 |
| Katalog-Nr.GC34341 |
PROTAC ERα Degrader-1 umfasst eine Ubiquitin-E3-Ligase-Bindungsgruppe, einen Linker und eine Protein-Bindungsgruppe. PROTAC ERα Abbauer-1-Extrakte aus Patent WO2017201449A1, Verbindung P1. PROTAC ERα Degrader-1 ist ein Östrogenrezeptor-alpha (ERα)-Degrader.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2417369-94-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.
Treatment of the HER2 expressing cells with the PROTAC ERα Degrader-1 (without Ab; compound P1) results in a decreased estrogen receptor-alpha (ERα) levels[1].
[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *